| 1JST | D:309-427; D:309-427 | PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
| 1JSU | B:309-427 | P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
| 1OGU | D:309-427; D:309-427 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR |
| 1OI9 | D:309-427; D:309-427 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OIU | D:309-427; D:309-427 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OIY | D:309-427; D:309-427 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OKV | D:309-427; D:309-427 | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2 |
| 1OKW | D:309-427; D:309-427 | CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2 |
| 1OL1 | D:309-427; D:309-427 | CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2 |
| 1P5E | D:309-427; D:309-427 | THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS) |
| 1PKD | D:309-427; D:309-427 | THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
| 1QMZ | D:309-427; D:309-427 | PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
| 1URC | D:309-427; D:309-427 | CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY |
| 1VYW | D:309-427; D:309-427 | STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 |
| 2UUE | D:309-427; D:309-427 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
| 2UZB | D:309-427; D:309-427 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZD | D:309-427; D:309-427 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZE | D:309-427; D:309-427 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZL | D:309-427; D:309-427 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2V22 | D:309-427; D:309-427 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
| 2WEV | D:309-427; D:309-427 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WFY | D:309-427; D:309-427 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WHB | D:309-427; D:309-427 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WIH | D:309-427; D:309-427 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 |
| 2WIP | D:309-427; D:309-427 | STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID |
| 2WMA | D:309-427; D:309-427 | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
| 2WMB | D:309-427; D:309-427 | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
| 2WPA | D:309-427; D:309-427 | OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING |
| 2WXV | D:309-427; D:309-427 | STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR |
| 2X1N | D:309-427; D:309-427 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2JGZ | B:300-418 | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B |
| 2W96 | A:155-265 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W99 | A:155-267 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W9F | A:155-261 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W9Z | A:155-267 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 1W98 | B:229-351 | THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E |
)
)